Tripathy D, Sohn J, Im S-A, et al. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial. SABCS 2017, GS2-05.
Voorspellende biomarkers hand-voetsyndroom en effectiviteit pyridoxine
jul 2017 | Borstkanker, Maag-darm-leveroncologie